Genomics Sells Nearly 30,000 Shares: Investor Signal for Genomics Stocks
A CEO’s large stock sale can spark questions about a company’s trajectory. This guide breaks down what genomics sells...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
119 articles
These Cheap Biotech Stocks Signal Low-Beta Growth Potential
Two affordable biotech names are drawing attention for potential low-beta growth as AI-driven tools reshape pipelines...
Exclusive: Perceptic Aims to Automate Drug Discovery
Perceptic, a London-founded startup formed by former Palantir Life Sciences executives, launches from stealth with a ...
Lantern Pharma (LTRN) 2025 Investment Outlook and Updates
Investing in early-stage biotech requires a steady playbook. This article breaks down Lantern Pharma (LTRN) in 2025, ...
Could Viking Therapeutics Next: Will It Challenge Lilly?
The race to own the GLP-1 weight loss market has a new challenger in Viking Therapeutics. This article breaks down wh...
Can Lilly Stock Reach $1800 by 2030? Bulls See Path
Eli Lilly kicked off 2026 with blockbuster sales and higher guidance, reigniting talk of a path to $1800 for Lilly st...
Best Weight Loss Drug Stocks to Buy in 2026: Top Picks
As GLP-1 therapies reshape obesity treatment, investors eye the best weight loss drug stock bets for 2026. This guide...
Jurassic Park Isn’t Just a Movie, Startups Hatch Chicks
A de-extinction startup says it hatched 26 live chicks in a lab using a synthetic eggshell, spotlighting frontier bio...
Iridex (IRIX) 2026 Earnings: Q1 Review & Outlook Guide
A clear, investor-friendly look at Iridex's Q1 2026 performance and what it could mean for the full year. Learn the n...
What This Fund’s Million Exit Signals Fresh Investor Cues
A major fund’s exit from Ocular Therapeutix raises questions about timing, liquidity, and sector signals. This articl...
Dyne Therapeutics 40% Rally Faces Fund Selloff Questions
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
This Beaten-Down Growth Stock Could Jump 30%, According to Wall Street
A high-flying biotech spin-off has faced a brutal disconnect between hype and reality. This beaten-down growth stock ...